NDA 020838 · Ani Pharms
Atacand
Candesartan Cilexetil · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jun 24, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Jun 4, 1998
Approved uses
5
Original approval plus efficacy supplements
Registered trials
176
52 Phase 3, 9 recruiting
FAERS reports
26,474
23,278 serious, 2,476 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue candesartan cilexetil as soon as possible [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue candesartan cilexetil as soon as possible. ( 5.1 , 8.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )
What it is approved for
From the label in effect Jan 15, 2026.
Candesartan cilexetil is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . Treatment of heart failure (NYHA class II-IV); candesartan cilexetil reduces cardiovascular death and heart failure hospitalization (1.2). 1.1 Hypertension Candesartan cilexetil is indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other...
Mechanism: Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 22, 2009 Supplement 31 · Efficacy · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Amendment 2
- May 18, 2005 Supplement 22 · Efficacy · priority review LabelLetter
- Feb 22, 2005 Supplement 24 · Efficacy · priority review LabelLetter
- Sep 13, 2002 Supplement 15 · Efficacy LabelReviewLetter
- Jun 4, 1998 Original approval · Type 1 - New Molecular Entity LabelOther Important Information from FDAPediatric Medical Review
4 products under this application
- ATACAND · CANDESARTAN CILEXETIL 16MG · TABLET, ORAL · Prescription · TE AB
- ATACAND · CANDESARTAN CILEXETIL 4MG · TABLET, ORAL · Prescription · TE AB
- ATACAND · CANDESARTAN CILEXETIL 32MG · TABLET, ORAL · Prescription · TE AB
- ATACAND · CANDESARTAN CILEXETIL 8MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Candesartan Cilexetil" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVDPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT05169021 · 15,000 participants (planned) · Start Dec 31, 2021 · Primary completion Dec 31, 2024
Drug: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy; Amlodipine folic acid 5.8mg+standard antihypertensive therapy and 2 more · For: Cerebral Small Vessel Diseases; Stroke
Sites: Beijing, China
- Heart Outcomes Prevention Evaluation-3Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT00468923 · 12,705 participants · Start May 2007 · Primary completion Dec 2015
Drug: Candesartan/HCT; Rosuvastatin · For: Cardiovascular Disease; Stroke
Sites: Hamilton, Canada
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00634400 · 6,268 participants (planned) · Start Mar 1999 · Primary completion May 2003
Drug: Candesartan; Placebo · For: Congestive Heart Failure
- Diabetic Retinopathy Candesartan TrialsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00252733 · 5,238 participants · Start Jun 2001 · Primary completion Apr 2008
Drug: candesartan cilexetil · For: Type 1 Diabetes
Sites: Herston, Australia; Perth, Australia; Odense, Denmark
- Recurrent Stroke Prevention Clinical Outcome StudyPivotal-lookingStatus unknown
Biomedis International Ltd.Academic, hospital or other
NCT01198496 · 5,000 participants (planned) · Start Oct 2010 · Primary completion Dec 2017
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone · For: Hypertension; Stroke; Blood Pressure
Sites: Shimotsuke, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea1,752
- fatigue1,751
- nausea1,666
- headache1,637
- drug ineffective1,623
- dizziness1,519
- diarrhoea1,389
- malaise1,380
- off label use1,330
- fall1,296
- pain1,249
- vomiting1,164
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 461 |
| 2005 | 543 |
| 2006 | 609 |
| 2007 | 853 |
| 2008 | 909 |
| 2009 | 1,077 |
| 2010 | 1,382 |
| 2011 | 2,050 |
| 2012 | 2,398 |
| 2013 | 1,086 |
| 2014 | 988 |
| 2015 | 977 |
| 2016 | 843 |
| 2017 | 815 |
| 2018 | 1,332 |
| 2019 | 1,424 |
| 2020 | 1,455 |
| 2021 | 1,261 |
| 2022 | 1,313 |
| 2023 | 1,225 |
| 2024 | 1,243 |
| 2025 | 1,195 |
| 2026 | 1,034 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Atacand (Candesartan Cilexetil)
2024 spending
$1.8M
Beneficiaries
649
2,894 claims
Per beneficiary
$2,718
$8.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,108,482 |
| 2021 | $2,636,639 |
| 2022 | $2,230,939 |
| 2023 | $2,033,228 |
| 2024 | $1,764,048 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment.
Soh MS, Won KH, Kim JJ, et al. · Sci Rep 2024 · Randomized Controlled Trial, Multicenter Study
- The safety and tolerability of candesartan cilexetil in CHF.
Erdmann E, George M, Voet B, et al. · J Renin Angiotensin Aldosterone Syst 2000 · Meta-Analysis
- Impaired endothelial function of the retinal vasculature in hypertensive patients.
Delles C, Michelson G, Harazny J, et al. · Stroke 2004 · Clinical Trial, Randomized Controlled Trial
- [Efficacy of candesartan cilexetil in hypertensive patients with or without diabetes].
El Féghali R, Nisse-Durgeat S, Asmar R · Arch Mal Coeur Vaiss 2007 · English Abstract, Meta-Analysis
- Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Simonetti GD, von Vigier RO, Konrad M, et al. · Pediatr Nephrol 2006 · Clinical Trial, Research Support, Non-U.S. Gov't
- Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.
Baguet JP, Legallicier B, Auquier P, et al. · Clin Drug Investig 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.